AGM/EGMMay 28, 2026, 05:17 PM
Cellectar Biosciences to vote on 39.6M warrant exercise, 2M share plan
AI Summary
Cellectar Biosciences, Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on July 7, 2026. Key proposals include the election of two Class III directors, the approval of an increase of 2,000,000 shares for the 2021 Stock Incentive Plan, and a crucial vote on the exercise of warrants for up to 39,618,078 shares of common stock. Stockholders will also vote on ratifying Deloitte & Touche, LLP as the independent auditor and an advisory vote on executive compensation. The company noted that current dilution is 3.9%, which could increase to 16.4% if the stock incentive plan is approved.
Key Highlights
- Annual Meeting of Stockholders to be held virtually on July 7, 2026.
- Proposes approval for exercise of warrants for up to 39,618,078 common shares.
- Seeks to increase 2021 Stock Incentive Plan shares by 2,000,000.
- 7,991,812 common shares outstanding as of May 19, 2026 Record Date.
- Current dilution is 3.9%; potential dilution rises to 16.4% if plan approved.
- Nominated Andrew Gu and Douglas J. Swirsky as Class III directors.
- Stefan D. Loren to retire from the Board of Directors.
- Proposes ratification of Deloitte & Touche, LLP as 2026 auditor.
Price Impact
More from CLRB